MagForce

: MF6

Market Cap€0m

Last Close -0.02

MagForce is a German med-tech firm with a CE-mark approved nanotechnology cancer treatment. This consists of NanoTherm (iron nanoparticles), Nanoplan (software) and NanoActivator (a device that produces a powerful magnetic field to heat the nanoparticles, which destroys or sensitises tumour cells to therapy).

More MagForce content >

Investment summary

Edison Investment Research is terminating coverage on Mercia Asset Management (MERC), Bloc Ventures (unlisted), YOC (YOC.DE), Genuit Group (GEN), AlzeCure Pharma (ALZCUR), abrdn Latin American Income Fund (ALAI), Magforce (MF6), OPG Power Ventures (OPG) and paragon (PGN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2020A 0.6 19.3 (9.7) (0.35) N/A N/A
2021A 0.4 (6.1) (8.9) (0.30) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A
Content on MagForce
MagForce – Primed to execute on its growth strategy
Healthcare | research QuickView | 10 November 2021
header_29
MagForce – Primed to execute on its growth strategy
Healthcare | research Update | 10 November 2021
header_29
MagForce – Time to capitalise on growth potential
Healthcare | research Update | 14 July 2021
header_29
View more
Register to receive research on MagForce as it is published
Share price graph
Balance sheet
Forecast net debt (€m) N/A
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (81.2) (99.1) (99.5)
Relative* (81.1) (99.0) (99.4)
52-week high/low €3.6/€0.0
*% relative to local index
Key management
Ben Lipps Chairman & CEO
Christian von Volkmann CFO
Barbara von Frankenberg VP Communications & Investor Relations